<DOC>
	<DOCNO>NCT01094171</DOCNO>
	<brief_summary>The purpose study assess reactogenicity safety simultaneous administration GSK Biologicals ' inactivated poliomyelitis vaccine Poliorix GSK Biologicals ' DTPa-vaccine Infanrix vaccine healthy child Russian Federation first year life accord National Calendar Prophylactic Immunisation Russian Federation .</brief_summary>
	<brief_title>Study Evaluate Safety Co-administration GSK Biologicals ' Poliorix Infanrix Healthy Children Russia</brief_title>
	<detailed_description />
	<mesh_term>Poliomyelitis</mesh_term>
	<criteria>Subjects investigator believe parents/guardians comply requirement protocol enrol study . A male female age 3 month include time vaccination . Written inform consent obtain parent subject . Healthy subject establish medical history clinical examination thermometry enter study , n't contraindication vaccination diphtheria , tetanus , pertussis poliomyelitis Use investigational nonregistered product ( drug vaccine ) study vaccine within 30 day precede booster dose study vaccine , plan use study period . Chronic administration ( defined 14 day ) immunosuppressant immunemodifying drug birth . Administration immunoglobulins and/or blood product birth plan administration study period . Planned administration/ administration vaccine foreseen study protocol within 30 day vaccination , except recombinant hepatitis B vaccine , Haemophilus influenzae type B vaccine seasonal/pandemic influenza prophylactic . Participation another clinical study time study , subject expose investigational nonregistered product ( pharmaceutical product device ) . Previous vaccination diphtheria , tetanus , pertussis poliomyelitis reason make timeframe stated National Calendar Prophylactic Vaccines Russian Federation . Medical history convulsion progressive neurological disease . Any confirm suspected immunosuppressive immunodeficient condition , base physical examination ( laboratory testing require ) . History allergic disease reaction likely exacerbate component vaccine . Chronic disease serious congenital defect . Acute disease time enrolment .</criteria>
	<gender>All</gender>
	<minimum_age>3 Months</minimum_age>
	<maximum_age>6 Months</maximum_age>
	<verification_date>March 2017</verification_date>
	<keyword>poliomyelitis</keyword>
	<keyword>diphtheria</keyword>
	<keyword>Primary immunization</keyword>
	<keyword>pertussis</keyword>
	<keyword>Children</keyword>
	<keyword>tetanus</keyword>
</DOC>